Healthcare provider profile · identity verified

William H Ranum, MD

Family Practice · WAUNAKEE, WI · NPI 1043267172

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	355	100
Simvastatin	Simvastatin	228	61
Omeprazole	Omeprazole	214	58
Lisinopril	Lisinopril	203	60
Levothyroxine Sodium	Levothyroxine Sodium	171	42
Hydrochlorothiazide	Hydrochlorothiazide	146	46
Amlodipine Besylate	Amlodipine Besylate	142	44
Metoprolol Succinate	Metoprolol Succinate	114	34
Losartan Potassium	Losartan Potassium	111	33
Sertraline Hcl	Sertraline Hcl	107	20
Tamsulosin Hcl	Tamsulosin Hcl	103	31
Allopurinol	Allopurinol	98	24
Albuterol Sulfate Hfa	Albuterol Sulfate	91	28
Atenolol	Atenolol	91	30
Metoprolol Tartrate	Metoprolol Tartrate	88	26
Trazodone Hcl	Trazodone Hcl	86	26
Fluoxetine Hcl	Fluoxetine Hcl	85	16
Prednisone	Prednisone	84	44
Metformin Hcl	Metformin Hcl	82	23
Furosemide	Furosemide	81	30
Gabapentin	Gabapentin	80	27
Metformin Hcl Er	Metformin Hcl	79	21
Warfarin Sodium	Warfarin Sodium	71	19
Citalopram Hbr	Citalopram Hydrobromide	70	18
Eliquis	Apixaban	63	17
Fluticasone Propionate	Fluticasone Propionate	60	22
Clopidogrel	Clopidogrel Bisulfate	53	16
Lorazepam	Lorazepam	51	18
Famotidine	Famotidine	50	12
Terazosin Hcl	Terazosin Hcl	50	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	46	22
Cephalexin	Cephalexin	45	22
Montelukast Sodium	Montelukast Sodium	41	13
Enalapril Maleate	Enalapril Maleate	39	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	39	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	39	17
Doxycycline Hyclate	Doxycycline Hyclate	37	28
Amoxicillin	Amoxicillin	36	22
Mirtazapine	Mirtazapine	36	suppressed
Hydrocortisone	Hydrocortisone	35	13
Ozempic	Semaglutide	35	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	34	suppressed
Bupropion Xl	Bupropion Hcl	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	14
Potassium Chloride	Potassium Chloride	31	13
Finasteride	Finasteride	30	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	29	suppressed
Spironolactone	Spironolactone	29	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	28	suppressed
Ketoconazole	Ketoconazole	28	14
Azithromycin	Azithromycin	27	20
Carvedilol	Carvedilol	26	suppressed
Naproxen	Naproxen	26	suppressed
Alendronate Sodium	Alendronate Sodium	24	suppressed
Alprazolam	Alprazolam	24	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Xarelto	Rivaroxaban	24	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	23	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	23	suppressed
Memantine Hcl	Memantine Hcl	23	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	11
Benazepril Hcl	Benazepril Hcl	21	suppressed
Estradiol	Estradiol	21	suppressed
Ondansetron Odt	Ondansetron	20	suppressed
Testosterone Cypionate	Testosterone Cypionate	20	suppressed
Acyclovir	Acyclovir	19	suppressed
Fenofibrate	Fenofibrate,micronized	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	13
Donepezil Hcl	Donepezil Hcl	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	14
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Nitroglycerin	Nitroglycerin	17	13
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Baclofen	Baclofen	16	suppressed
Gemfibrozil	Gemfibrozil	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Glipizide	Glipizide	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Darifenacin Er	Darifenacin Hydrobromide	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Xultophy 100-3.6	Insulin Degludec/Liraglutide	14	suppressed
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Fentanyl	Fentanyl	13	suppressed
Bupropion Hcl	Bupropion Hcl	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Risperidone	Risperidone	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	11	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error